Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.39% | 49.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 99.98% | 101.36% | |||
| Operating Income | -99.98% | -101.36% | |||
| Income Before Tax | -5,907.34% | 106.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5,907.34% | 106.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5,907.34% | 106.44% | |||
| EBIT | -99.98% | -101.36% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -5,224.56% | 104.64% | |||
| Normalized Basic EPS | -5,169.44% | 104.69% | |||
| EPS Diluted | -5,233.33% | 104.58% | |||
| Normalized Diluted EPS | -5,630.30% | 104.30% | |||
| Average Basic Shares Outstanding | 14.15% | 37.79% | |||
| Average Diluted Shares Outstanding | 5.97% | 48.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||